sensit
humor
immun
respons
invad
virus
product
antivir
antibodi
form
part
host
antivir
repertoir
paradox
number
viral
pathogen
certain
condit
antibodi
provid
attract
mean
enhanc
viru
entri
replic
number
cell
type
known
antibodydepend
enhanc
ade
infect
phenomenon
occur
virusantibodi
immunocomplex
interact
cell
bear
complement
fc
receptor
promot
intern
viru
increas
infect
frequent
associ
exacerb
viral
diseas
ade
infect
present
major
obstacl
prevent
viral
diseas
vaccin
thought
partli
respons
advers
effect
novel
antivir
therapeut
intraven
immunoglobulin
grow
bodi
work
examin
intracellular
signal
pathway
epitop
respons
mediat
ade
view
aid
ration
design
antivir
strategi
vitro
studi
also
confirm
ade
featur
infect
grow
number
virus
challeng
remain
understand
multilay
molecular
mechan
ade
effect
viral
pathogenesi
earli
stage
viral
infect
cycl
requir
attach
entri
virus
host
cell
classic
viru
attach
mediat
specif
bind
viral
surfac
protein
host
cell
receptor
molecul
concentr
viru
cell
plasma
membran
virus
often
stud
one
multipl
surfac
protein
potenti
contain
numer
subdomain
promot
interact
cellular
receptor
stimul
viru
entri
cell
howev
viru
surfac
also
highli
antigen
structur
trigger
cellular
humor
immun
respons
erad
viru
host
antibodi
contribut
sever
level
antivir
defens
effect
neutral
viru
reduc
infect
neutral
infect
target
viral
glycoprotein
gp
envelop
virus
protein
shell
nonenvelop
virus
envelop
virus
may
either
block
virion
bind
cellular
receptor
interfer
fusion
machineri
aggreg
viru
particl
nonenvelop
virus
may
prevent
uncoat
viral
genom
endosom
promot
cytosol
degrad
incom
virion
tripartit
motifcontain
protein
proteasom
pathway
two
model
propos
describ
kinet
neutral
first
singlehit
model
postul
bind
singl
antibodi
molecul
critic
site
virion
suffici
neutral
viru
second
wide
accept
multihit
model
propos
neutral
achiev
individu
virion
bound
number
antibodi
exce
stoichiometr
threshold
neutral
number
avail
epitop
specif
antibodi
virion
known
stoichiometri
neutral
calcul
howev
stoichiometr
threshold
neutral
determin
antibodi
affin
epitop
access
exampl
antibodi
specif
poorli
access
epitop
requir
higher
concentr
exceed
occup
threshold
neutral
paradox
howev
time
recogn
subneutr
concentr
antibodi
certain
condit
act
enhanc
viral
infect
aid
viral
entri
target
cell
mechan
improv
viru
uptak
term
antibodydepend
enhanc
ade
infect
thought
occur
viru
bound
nonneutr
antibodi
subneutr
concentr
antibodi
facilit
cell
entri
fcc
receptor
fccr
depend
manner
interact
protrud
antibodi
fc
antibodyviru
immunocomplex
fccr
myeloid
cell
monocyt
macrophag
dendrit
cell
dc
certain
granulocyt
typic
lead
phagocytosi
result
increas
number
infect
cellssocal
extrins
ade
form
ade
therefor
requir
prior
sensit
humor
immun
respons
wherebi
circul
antibodi
produc
primari
infect
recogn
bind
heterolog
serotyp
viru
enhanc
viral
infect
intern
virusantibodi
immunocomplex
cell
bear
fccr
rather
promot
viral
neutral
intern
immunocomplex
may
modul
innat
antivir
cell
respons
increas
viru
product
substanti
cell
process
term
intrins
ade
togeth
extrins
intrins
ade
thought
prompt
massiv
releas
inflammatori
vasoact
mediat
ultim
contribut
diseas
sever
throughout
review
refer
ade
overal
process
ade
infect
use
term
intrins
extrins
refer
specif
mechanist
process
first
report
ade
made
studi
examin
arboviru
neutral
antivir
antibodi
number
virus
flavivirida
togavirida
famili
show
enhanc
infect
assay
dilut
respect
antisera
later
work
fraction
sera
confirm
enhanc
princip
associ
igg
antibodi
abl
act
molecular
bridg
viru
fccrexpress
cell
capabl
bind
fc
portion
igg
seri
report
halstead
et
al
first
examin
pathogen
potenti
fccrdepend
ade
caus
dengu
hemorrhag
fever
dhf
dengu
shock
syndrom
dss
dengu
viru
denv
infect
epidemiolog
studi
vivo
vitro
model
halstead
et
al
establish
link
sever
form
denv
infect
individu
previou
dengu
infect
also
enhanc
infect
target
cell
diseas
exacerb
caus
denv
antibodi
opsonin
sinc
much
research
surround
viral
ade
focus
member
flavivirida
famili
particularli
denv
driven
lack
licens
denv
vaccin
effect
antivir
agent
treat
denv
infect
ade
infect
implic
major
obstacl
vaccin
develop
number
virus
caus
signific
human
health
threat
includ
denv
addit
separ
mechan
extrins
ade
identifi
involv
classic
complement
pathway
identifi
use
flaviviru
studi
found
complement
receptor
abl
mediat
igmdepend
enhanc
west
nile
viru
wnv
infect
macrophag
form
complementmedi
ade
subsequ
describ
number
viruscel
system
includ
human
immunodefici
enhanc
infect
tlymphoblastoid
cell
line
presenc
subneutr
level
hivspecif
antibodi
shown
requir
high
level
express
although
mechan
thought
mutual
exclus
enhanc
infect
complementdepend
ade
distinct
fccrdepend
ade
addit
ade
independ
rout
complementmedi
ade
infect
shown
requir
complement
compon
interact
virusantibodi
immunocomplex
enhanc
product
infect
vitro
similar
mechan
ade
report
enhanc
infect
ebola
viru
nonmonocyt
cell
promot
bind
viru
attach
target
cell
endocytosi
igg
antibodi
report
bind
viral
epitop
close
proxim
allow
bind
fc
portion
antibodi
immunocomplex
bind
receptor
cell
surfac
enhanc
infect
hiv
opson
complement
alon
also
report
form
ade
complementdepend
ade
infect
also
link
viral
pathogenesi
patient
level
enhanc
antibodi
complementrestor
serum
sampl
correl
immunosuppress
diseas
moreov
greater
varieti
cell
type
express
complement
receptor
fccr
gener
restrict
cell
myeloid
lineag
may
therefor
possibl
complementdepend
ade
caus
aberr
viral
infect
typic
thought
nontarget
cell
turn
infect
nontarget
cell
result
complementdepend
ade
may
precursor
viral
pathogenesi
atyp
often
sever
diseas
symptom
associ
chronic
recurr
viral
infect
inde
enhanc
uptak
human
parvoviru
endotheli
cell
myocardium
like
due
ade
mediat
complement
factor
receptor
associ
acut
chronic
inflammatori
cardiomyopathi
therefor
despit
strong
host
tropism
erythroid
progenitor
cell
complementdepend
ade
human
parvoviru
confer
increas
viru
endotheli
cell
uptak
presenc
human
parvoviru
antibodi
ade
known
featur
infect
mani
virus
howev
proven
difficult
rigor
test
occurr
import
ade
vivo
area
requir
work
addit
littl
known
mechan
structur
interact
underli
ade
fccrdepend
ade
current
thought
commonli
use
mechan
ade
among
virus
discuss
detail
review
recent
studi
begun
investig
upstream
downstream
molecular
signal
event
surround
form
viral
ade
light
current
data
discuss
review
effect
signal
cascad
innat
cellular
immun
viral
pathogenesi
continu
focu
research
effort
highlight
recent
advanc
made
develop
permiss
model
system
examin
role
fcr
mediat
viral
ade
fcrtarget
therapeut
strategi
treatment
viral
pathogenesi
rise
rainfal
acceler
global
warm
provid
breed
ground
conduc
mosquito
vector
lead
spread
arthropodborn
diseas
differ
part
world
recent
world
hit
wave
mosquitotransmit
diseas
caus
alphaviru
flaviviru
infect
arthritogen
alphavirus
chikungunya
viru
chikv
ross
river
viru
rrv
sindbi
viru
sinv
caus
febril
ill
myalgia
polyarthralgia
clinic
hallmark
last
month
year
infect
rrv
sinv
endem
australia
europ
respect
chikv
caus
larg
outbreak
mani
part
world
includ
america
africa
southeast
asia
india
oceania
affect
million
individu
worldwid
moreov
denv
wnv
promin
flavivirus
major
health
concern
due
sever
diseas
caus
denv
geograph
distribut
similar
chikv
caus
massiv
worldwid
outbreak
estim
million
peopl
suffer
denv
infect
annual
denv
infect
typic
selflimit
howev
case
infect
diseas
manifest
complic
sever
form
patient
may
suffer
plasma
leakag
shock
syndrom
unattend
sever
case
denv
infect
lead
mortal
rate
contrast
denv
wnv
endem
america
europ
africa
middl
east
although
approxim
wnv
infect
subclin
symptomat
infect
known
wnv
fever
persist
month
post
infect
patientsdevelop
sever
neurolog
complic
may
fatal
whether
associ
ade
known
evid
vitro
studi
ade
alphavir
infect
report
sinc
peiri
porterfield
demonstr
clear
antibodydepend
plaqu
enhanc
macrophag
infect
semliki
forest
viru
sinv
presenc
subneutr
concentr
homolog
antibodi
consist
studi
chana
et
al
demonstr
vitro
infect
macrophagelik
cell
express
fc
receptor
sinv
togeth
high
dilut
antisinv
monoclon
antibodi
mab
led
increas
plaqu
format
macrophag
identifi
key
player
facilit
arthritogen
alphavir
diseas
progress
larg
due
permiss
alphavir
infect
persist
alphaviru
within
macrophag
late
phase
infect
suggest
like
occurr
ade
inde
sever
studi
rrv
demonstr
ade
macrophag
serum
recov
rrvinfect
patient
contain
antirrv
antibodi
dilut
subneutr
level
promot
infect
lesspermiss
monocyt
cell
line
mono
mac
enhanc
rrv
infect
highli
permiss
macrophag
cell
line
addit
infect
fcrexpress
cell
led
persist
viru
product
day
post
infect
mechanist
studi
lidburi
et
al
shed
light
role
rrvinduc
ade
pathway
modul
host
transcript
translat
immun
respons
trigger
lipopolysaccharid
lp
stimul
macrophag
cell
cultur
prior
rrv
infect
significantli
reduc
rrv
replic
howev
rrv
infect
presenc
antirrv
antibodi
abolish
lpsinduc
antivir
effect
allow
rrvade
infect
cell
increas
viru
replic
phenomenon
due
inhibit
transcript
factor
nuclear
factorjb
nfjb
interferon
regulatori
factor
irf
paradox
express
usual
driven
nfjb
translat
express
tumor
necrosi
factor
tnf
gener
reactiv
nitrogen
intermedi
downstream
studi
identifi
activ
viral
replic
rrvade
infect
crucial
suppress
lpsinduc
activ
transcript
factor
protein
complex
signal
transduc
activ
transcript
stat
well
elev
interleukin
il
express
recent
anim
studi
conduct
use
chikv
also
demonstr
evid
ade
chikv
infect
singl
immun
mice
chikv
vaccin
candid
led
low
titer
antichikv
igg
product
host
give
rise
earli
diseas
onset
upon
challeng
repres
acut
foot
swell
inflamm
date
therapeut
strategi
vaccin
current
avail
treatment
arthrtitogen
alphavir
diseas
light
occurr
ade
infect
alphavirus
caution
exercis
vaccin
clinic
trial
avoid
advers
health
impact
denv
made
four
differ
serotyp
halstead
orourk
first
identifi
ade
denv
infect
observ
nondenv
suscept
humanor
rhesu
monkeyderiv
primari
peripher
blood
mononuclear
cell
pbmc
could
success
infect
denv
presenc
high
dilut
antidenv
antibodi
crossreact
antidenv
antibodi
gener
exposur
differ
denv
serotyp
later
shown
mediat
ade
occurr
ade
long
associ
sever
denv
diseas
pathogenesi
give
rise
sever
form
diseas
dhf
dsstypic
secondari
infect
commonli
order
follow
secondari
infect
discuss
detail
later
primari
denv
infect
infant
nonneutr
titer
antidenv
antibodi
acquir
matern
transmiss
denvimmun
mother
reportedli
led
sever
dhf
evid
ade
exacerb
denv
infect
report
moi
et
al
serum
specimen
collect
denv
patient
primari
secondari
infect
viru
titer
measur
serum
specimen
secondari
denvinfect
patient
approxim
higher
serum
patient
primari
infect
detect
use
fccrexpress
bhk
cell
date
denv
one
extens
studi
virus
relat
ade
infect
due
part
global
preval
dengu
infect
sinc
flavivirus
wnv
also
associ
ade
infect
denv
key
event
facilit
wnvmediat
ade
infect
bind
virion
antibodi
subneutr
concentr
cardosa
et
al
previous
character
dual
role
antiwnv
antibodi
neutral
enhanc
wnv
infect
depend
antibodi
titer
class
isotyp
correl
earlier
studi
conduct
peiri
et
al
besid
devast
pandem
centuri
caus
influenza
viru
two
subsequ
episod
caus
sever
million
death
worldwid
respiratori
virus
continu
pose
seriou
threat
public
health
recent
year
illustr
global
impact
sever
acut
respiratori
syndrom
coronaviru
sarscov
outbreak
equal
concern
confirm
human
case
avian
influenza
mani
countri
particularli
across
asia
strain
avian
influenza
jump
human
china
emerg
influenza
pandem
well
novel
coronaviru
caus
agent
middl
east
respiratori
syndrom
merscov
event
trigger
score
investig
gain
insight
pathogen
mechan
underli
sever
symptom
high
fatal
rate
sar
mer
avian
influenza
one
concept
driven
research
area
recognit
host
immun
system
essenti
clear
infect
may
sometim
mediat
excess
dysregul
respons
contribut
sever
clinic
symptom
prognosi
affect
individu
immunopatholog
respons
exemplifi
socal
cytokin
storm
trigger
highli
pathogen
avian
influenza
consid
one
primari
caus
sever
spanish
flu
pandem
patholog
sar
patient
also
appear
least
partial
immunemedi
therefor
sever
studi
investig
whether
host
immun
respons
may
involv
develop
sever
respiratori
diseas
sarscov
member
coronavirida
famili
singlestrand
positivesens
rna
virus
caus
wide
varieti
ill
rang
respiratori
gastrointestin
system
diseas
broad
rang
host
includ
bird
felin
pig
cow
turkey
dog
usual
agre
sarscov
addit
infect
respiratori
tract
may
also
directli
infect
immun
cell
express
angiotensin
iconvert
enzym
receptor
recogn
sarscov
spike
protein
mediat
viru
entri
rais
possibl
antibodymedi
entri
may
provid
sarscov
opportun
broaden
target
option
possibl
first
suggest
studi
describ
sarscov
vaccin
candid
base
recombin
fulllength
sarscov
spike
proteinth
major
antigen
protein
four
viru
structur
protein
induc
neutral
protect
antibodi
trigger
infect
human
b
cell
line
despit
elicit
neutral
protect
immun
respons
rodent
monitor
suscept
human
pbmc
infect
sarscov
spikepseudotyp
lentivir
particl
sarscovpp
well
replicationcompet
sarscov
occurr
ade
establish
differ
cell
line
circul
immun
cell
type
among
monocyt
lineag
cell
primari
target
addit
monocyt
human
macrophag
also
infect
sarscov
presenc
antispik
antibodi
ademedi
infect
macrophag
howev
support
product
replic
viru
significantli
affect
express
profil
cytokineschemokin
involv
initi
inflammatori
respons
mechanist
studi
deciph
molecular
correl
ade
viral
infect
focus
either
identifi
immun
receptor
andor
serum
compon
allow
penetr
pathogen
target
cell
ie
extrins
ade
outcom
respons
target
cell
downstream
extrins
ade
infect
ie
intrins
ade
vitro
infect
sarscov
opson
antispik
serum
enhanc
via
fccriia
lesser
extent
similarli
infect
primari
felin
macrophag
enhanc
felin
infecti
periton
viru
opson
antispik
antibodi
abrog
block
antibodi
fc
receptor
construct
truncat
chimer
fcr
molecul
reveal
bind
sarscovpp
cell
via
extracellular
domain
fccr
suffici
trigger
ade
infect
entri
requir
intact
intracellular
domain
although
relationship
intern
immun
complex
ade
infect
sarscov
via
fccrii
appear
complex
process
observ
chang
tropism
sarscov
presenc
antivir
immun
serum
distinguish
ade
sarscov
infect
mani
exampl
antibodymedi
viral
infect
presenc
antivir
antibodi
increas
viral
load
due
infect
higher
number
alreadi
suscept
cell
note
neutral
endosom
acid
ph
led
exacerb
antibodymedi
infect
contrast
previous
describ
sarscov
infect
mediat
receptor
possibl
viral
particl
infect
cell
ade
pathway
remain
trap
acid
compart
inhibit
endosom
acidif
prevent
degrad
altern
abil
spike
mediat
cell
membran
fusion
neutral
ph
could
allow
antibodyopson
sarscovpp
fuse
endosom
membran
regardless
mechan
biochem
requir
fccrmediat
infect
markedli
distinct
underli
viru
receptordepend
entri
illustr
novel
mechan
addit
sarscov
enter
target
cell
date
whether
ade
occur
sarscov
infect
infect
individu
still
controversi
sever
clinic
studi
report
sarscovspecif
antibodi
found
sar
patient
harm
wherea
other
observ
poor
diseas
outcom
earli
seroconvert
sar
patient
address
issu
directli
would
necessari
screen
sar
patient
sera
keep
mind
possibl
ade
may
occur
within
narrow
window
cours
infect
subset
infect
patient
one
remain
awar
howev
possibl
consequ
altern
infect
pathway
coronavirus
besid
sarscov
appear
abl
jump
speci
vaccin
remain
one
option
avail
prevent
spread
infect
caus
famili
virus
influenza
virus
type
b
c
envelop
virus
neg
singlestrand
rna
segment
genom
belong
orthomyxovirida
famili
respons
wide
rang
ill
endem
demonstr
pandem
potenti
annual
vaccin
million
peopl
worldwid
possibl
occurr
ade
import
implic
year
pass
sinc
public
first
studi
report
ade
influenza
experiment
rat
model
heterolog
challeng
follow
immun
initi
observ
soon
follow
similar
report
mous
macrophag
cell
line
notic
antibodi
hemagglutinin
ha
neuraminidas
na
two
main
structur
compon
viral
envelop
abl
induc
ade
influenza
virus
ha
nainclud
distinct
lineag
influenza
virus
identifi
new
world
bat
therefor
sever
subtyp
test
reveal
enhanc
activ
straindepend
fcrmediat
although
almost
studi
carri
use
mous
cell
line
sever
instanc
increas
sever
clinic
diseas
observ
immun
anim
especi
pig
recent
ferret
anim
model
regard
accur
reproduc
human
infect
challeng
heterolog
strain
although
directli
test
ade
present
like
explan
occurr
infectionenhanc
antibodi
human
suggest
one
studi
compar
impact
sera
vaccin
natur
infect
individu
uptak
influenza
viru
experi
show
natur
infect
attenu
vaccineinduc
antibodi
enhanc
uptak
homolog
viru
well
viru
isol
sever
year
later
viral
titer
significantli
higher
challeng
cell
presenc
sera
vaccin
group
point
possibl
induct
ade
despit
lack
evid
vaccineinduc
ade
human
pandem
sever
observ
studi
rais
possibl
prior
antiinfluenza
vaccin
associ
enhanc
risk
medic
attend
laboratoryconfirm
diseas
find
extend
random
blind
placebocontrol
ferret
studi
whose
conclus
corrobor
hypothesi
direct
advers
effect
prior
administr
trival
inactiv
influenza
vaccin
subsequ
infect
pandem
viru
pdm
although
author
assess
whether
ade
involv
caution
result
ferret
may
extrapol
explain
human
case
observ
warrant
investig
differ
experiment
model
issu
revisit
compar
infect
mous
macrophagelik
cell
line
differ
subset
human
macrophag
panel
sera
patient
receiv
differ
influenza
vaccin
data
indic
heterolog
antibodi
facilit
entri
lentivirus
pseudotyp
highli
pathogen
ha
pdm
virus
murin
cell
line
infect
differ
influenza
viru
strain
show
classic
altern
activ
primari
human
macrophag
respect
permiss
viral
infect
absenc
antibodi
avian
virus
pdm
howev
evid
ade
influenza
either
subset
indic
event
may
pose
threat
vaccin
individu
addit
studi
report
signific
protect
induc
trival
inactiv
vaccin
clearli
safeti
univers
influenza
vaccin
remain
issu
studi
pig
identifi
crossreact
antibodi
induc
heterolog
inactiv
influenza
vaccin
target
immunodomin
epitop
close
fusion
peptid
lead
enhanc
pdm
viru
fusion
author
dub
phenomenon
vaccinationassoci
enhanc
respiratori
diseas
refrain
refer
ade
underli
mechan
although
present
evid
crossreact
antibodi
lead
enhanc
infect
due
viru
fusion
phinduc
conform
chang
ha
endosom
compart
despit
limit
acknowledg
author
identif
antibodi
correl
vaccineinduc
enhanc
viral
infect
therefor
presenc
monitor
evalu
immun
respons
develop
univers
influenza
vaccin
collect
result
suggest
although
previou
comparison
show
murin
macrophag
cell
line
behav
similar
way
human
monocyt
ade
influenza
virus
cell
typeand
hostspecif
underscor
need
thorough
character
cellular
model
util
differ
virus
human
respiratori
syncyti
viru
rsv
negativesens
singlestrand
rna
viru
famili
paramyxovirida
lead
caus
lower
respiratori
infect
neonat
children
viru
global
burden
season
epidem
effort
ongo
curb
incid
prevent
vaccin
sinc
initi
demonstr
formalininactiv
vaccin
actual
worsen
diseas
sever
children
possibl
ade
consid
immun
children
develop
subneutr
antibodi
titer
compar
compar
age
natur
rsv
infect
immun
first
hint
ade
could
underli
mechan
contribut
diseas
manifest
infant
came
vitro
studi
murin
human
macrophagelik
cell
line
use
thu
two
mab
specif
separ
surfac
gp
rsv
human
sera
contain
virusspecif
antibodi
found
enhanc
rsv
infect
note
abil
increas
viru
titer
greater
convalesc
sera
correl
antibodi
titer
phenomenon
could
revers
block
either
fc
segment
mab
fc
receptor
cell
suggest
involv
opson
viru
follow
bind
immun
complex
fc
receptor
target
cell
collect
report
indic
antibodymedi
enhanc
rsv
infect
occur
vitro
macrophag
evid
ade
possibl
mechan
diseas
manifest
follow
immun
formalininactiv
vaccin
rsv
obtain
macaqu
model
howev
sever
recent
studi
report
vaccineenhanc
diseas
exoner
ade
mechan
lung
immunopatholog
follow
formalininactiv
vaccin
mice
ascrib
distinct
tcell
subset
orchestr
discret
specif
diseas
manifest
result
deposit
immun
complex
start
lung
despit
obviou
differ
gener
immunopatholog
two
type
antibodydepend
diseas
share
common
trait
depend
inadequ
respons
innat
immun
system
trigger
either
natur
infect
vaccin
interestingli
formalininactiv
vaccin
human
metapneumoviru
induc
immunemedi
diseas
indic
may
common
featur
share
member
paramyxovirida
famili
includ
measl
viru
ebola
viru
nonseg
negativestrand
rna
viru
belong
filovirida
famili
respons
sever
hemorrhag
fever
high
fatal
rate
current
ebola
epidem
liberia
guinea
sierra
leon
largest
complex
ebola
outbreak
sinc
viru
first
discov
almost
confirm
probabl
suspect
case
death
avail
treatment
proven
efficaci
although
sever
trial
underway
develop
safe
vaccin
becom
one
main
area
research
context
use
review
evid
immun
envelop
gp
zair
strain
ebola
viru
induc
antibodi
respons
enhanc
viru
infect
vitro
although
evid
involv
ade
mechanist
explan
extrem
virul
ebola
viru
lack
observ
rais
concern
develop
safe
vaccin
subsequ
studi
reveal
sera
convalesc
patient
day
onset
symptom
enhanc
infect
primat
cell
hand
two
mab
zair
gp
produc
diametr
opposit
effect
ie
protect
ade
conclud
distinct
epitop
underli
featur
construct
chimer
envelop
gp
epitop
zair
strain
requir
ade
replac
correspond
sequenc
reston
ebola
viru
appear
caus
asymptomat
infect
human
abil
trigger
ade
drastic
reduc
enhanc
infect
mediat
novel
molecular
correl
requir
antibodi
direct
envelop
gp
interact
complement
factor
thu
bind
antibodi
complex
viru
therebi
favor
interact
receptor
consequ
increas
interact
cell
surfac
receptor
identifi
mammalian
cell
mechan
extend
rang
cell
becom
suscept
infect
well
beyond
rang
fc
receptorexpress
cell
immun
system
hypothes
ade
may
respons
rapid
dissemin
infect
secondari
target
ensu
exacerb
symptom
observ
rais
concern
develop
ebola
viru
vaccin
base
envelop
gp
use
passiv
therapi
convalesc
sera
howev
recent
studi
demonstr
potenti
risk
inher
disadvantag
use
whole
polyclon
serum
passiv
immun
therapi
overcom
specif
wellcharacter
mab
show
protect
efficaci
nonhuman
primat
model
ebola
viru
diseas
current
test
clinic
trial
addit
sever
vaccin
candid
shown
safeti
primat
model
roll
last
month
current
ebola
outbreak
vaccin
human
appear
achiev
immun
respons
compar
magnitud
associ
protect
nonhuman
primat
suggest
immunolog
data
could
use
demonstr
vaccin
efficaci
although
full
report
yet
appear
literatur
collect
observ
suggest
ade
ebola
may
complex
phenomenon
relat
balanc
differ
neutral
nonneutr
enhanc
antibodi
elicit
differ
immun
protocol
associ
ade
infect
sever
viral
diseas
remain
area
intens
studi
infectionenhanc
epitop
therefor
recogn
potenti
contribut
viral
pathogenesi
studi
antigen
determin
mediat
ade
envelop
virus
found
overwhelm
evid
role
epitop
within
surfac
structur
protein
antibodi
gener
envelop
protein
multipl
virus
shown
enhanc
infect
vitro
exampl
epitop
includ
spike
protein
sarscov
gp
hepat
c
viru
gp
ebola
viru
transmembran
gp
hiv
gp
porcin
reproduct
respiratori
syndrom
viru
mutat
analysi
epitop
map
allow
dissect
amino
acid
domain
within
protein
respons
ade
evid
also
exist
howev
infectionenhanc
antibodi
gener
intern
structur
protein
porcin
reproduct
respiratori
syndrom
viru
nucleocapsid
denv
premembran
prm
seem
like
protein
gener
conceal
viru
envelop
may
stimul
antigen
respons
due
abund
overexpress
natur
infect
releas
incomplet
immatur
virion
cell
notabl
also
antibodi
nonstructur
protein
promot
endotheli
cell
damag
via
antibodydepend
complementmedi
cytolysi
due
high
homolog
denv
cell
surfac
molecul
endothelium
platelet
well
blood
coagulationrel
molecul
express
virion
surfac
detect
infect
cell
surfac
serum
viral
serotyp
strain
even
member
viral
genu
famili
abl
present
common
epitop
infect
potenti
gener
antibodi
capabl
ademedi
infect
enhanc
increas
ade
infect
therefor
signific
obstacl
develop
effect
vaccin
number
viral
pathogen
understand
epitop
respons
enhanc
viral
infect
therefor
aid
develop
novel
vaccin
strategi
exampl
engin
vaccin
exclus
express
neutral
epitop
denv
compris
four
serotyp
antigen
crossreact
one
anoth
antibodi
elicit
primari
infect
one
serotyp
although
offer
lifelong
protect
serotyp
subneutr
caus
ade
upon
secondari
infect
serotyp
moreov
within
particular
denv
serotyp
divers
denv
genotyp
add
complex
elicit
antibodi
respons
amino
acid
sequenc
vari
like
exacerb
gener
quasispeci
dengu
infect
perhap
surprisingli
antibodi
respons
denv
infect
human
predominantli
crossreact
mani
nonneutr
potenti
ade
addit
live
attenu
denv
vaccin
candid
produc
similar
humor
respons
domin
serotyp
crossreact
weakli
neutral
antibodi
seen
denv
infect
safe
denv
vaccin
must
therefor
stimul
protect
denv
serotyp
els
risk
develop
sever
form
diseas
dhf
secondari
infect
multipl
studi
examin
differ
denv
serotyp
structur
aid
ration
design
vaccin
induc
neutral
antibodi
lower
risk
dhf
dss
hostderiv
denv
membran
dynam
structur
stud
multipl
copi
multidomain
envelop
e
gp
either
dimer
trimer
conform
membran
protein
immatur
viru
particl
contain
trimer
spike
made
heterodim
e
prm
protein
matur
undergo
furin
cleavag
leav
ctermin
transmembran
domain
associ
viru
particl
numer
studi
attempt
character
neutral
epitop
denv
structur
protein
serotypespecif
mab
denv
e
protein
reportedli
enhanc
neutral
activ
inde
potenti
therapeut
antibodi
recogn
epitop
domain
iii
diii
e
protein
shown
neutral
activ
denv
infect
also
flavivirus
across
heterolog
denv
genotyp
diiispecif
antibodi
howev
part
larger
antibodi
repertoir
whether
antibodi
contribut
denv
neutral
vivo
remain
contenti
issu
complic
ade
recent
studi
confirm
highli
crossreact
antibodi
neutral
enhanc
activ
domin
human
immun
respons
denv
infect
use
antibodydeplet
techniqu
studi
attempt
identifi
specif
viral
antigen
epitop
recogn
enhanc
human
antibodi
denv
infect
denvspecif
antibodi
subpopul
remov
primari
denvimmun
human
sera
effect
ade
examin
remov
serotyp
crossreact
antibodi
ablat
enhanc
heterotyp
viru
infect
vitro
vivo
confirm
crossreact
antibodi
bind
virion
structur
protein
main
antibodi
compon
human
immun
serum
respons
heterotyp
denv
enhanc
cell
cultur
ade
mous
model
specif
deplet
crossreact
ebind
antibodi
antibodi
predominantli
recogn
fusion
loop
region
e
dii
partial
decreas
enhanc
capac
immun
sera
heterotyp
serotyp
indic
addit
structur
protein
antibodi
play
role
ade
heterotyp
denv
infect
competit
ade
studi
use
prmspecif
fab
fragment
human
immun
sera
indic
e
protein
fusion
loop
prmspecif
antibodi
primari
denvimmun
sera
independ
contribut
enhanc
heterotyp
denv
infect
fccrmediat
ade
infect
shown
occur
antibodi
bind
denv
e
prm
protein
recent
advanc
human
hybridoma
technolog
confirm
enhanc
effect
human
antidenv
mab
past
larg
observ
mous
mab
advanc
allow
better
understand
humor
immun
respons
dengu
viru
infect
human
interestingli
human
hybridoma
could
deriv
cell
subject
infect
denv
year
prior
collect
peripher
blood
longterm
memori
b
cell
predomin
circul
found
encod
enhanc
antibodi
creat
potenti
ade
denv
infect
thu
diseas
enhanc
decad
initi
infect
antiprm
antibodi
shown
major
compon
human
serolog
respons
denv
infect
howev
antibodi
exhibit
limit
viru
neutral
capac
highli
crossreact
among
dengu
viru
serotyp
even
high
concentr
antiprm
unabl
fulli
neutral
denv
infect
potent
promot
ade
fcrbear
cell
ineffici
cleavag
prm
denv
process
result
rel
high
level
immatur
prmcontain
viru
particl
releas
infect
cell
therefor
like
ade
immatur
normal
noninfecti
denv
particl
antiprm
antibodi
facilit
effici
viru
bind
cell
entri
fc
receptorexpress
cell
concurr
partial
cleavag
prm
denv
exud
may
reduc
densiti
antigen
avail
viral
neutral
antiprm
antibodi
thu
antiprm
antibodi
may
enabl
infect
otherwis
inact
immatur
byproduct
infect
cell
via
ade
infect
interest
proposit
given
also
prm
antibodi
respons
shown
significantli
higher
patient
secondari
denv
infect
primari
infect
possibl
antiprmmedi
ade
denv
infect
contribut
sever
diseas
patholog
associ
secondari
infect
suggest
promot
antiprm
antibodi
respons
denv
benefit
immun
enhanc
also
immun
evas
strategi
addit
restor
infect
noninfecti
immatur
denv
prmspecif
antibodi
also
found
crossreact
cryptic
epitop
e
protein
locat
di
dii
junction
despit
unavail
nativ
function
fold
e
protein
cryptic
epitop
may
imped
e
protein
e
protein
subunitbas
immun
strategi
approach
may
unabl
complet
avoid
gener
antiprm
antibodi
enhanc
denv
infect
recent
studi
luo
et
al
analyz
antibodi
respons
individu
epitop
denv
prm
protein
use
epitop
map
bioinformat
analysi
five
epitop
peptid
chosen
immun
balbc
mice
librari
overlap
prm
peptid
mice
immun
peptid
span
amino
acid
prm
protein
name
produc
remark
high
titer
antibodi
recogn
epitop
overlap
sera
denvinfect
patient
indic
antibodi
respons
epitop
elicit
natur
denv
infect
interestingli
sera
show
limit
neutral
activ
signific
ade
activ
toward
four
denv
serotyp
fc
receptorposit
cell
similarli
crossreact
antibodi
poorli
neutral
potent
enhanc
infect
four
denv
serotyp
map
amino
acid
residu
denv
prm
protein
identif
infectionenhanc
epitop
understand
pathogenesi
associ
ade
infect
aid
ration
vaccin
design
viral
strainspecif
differ
pathogen
also
link
increas
infect
due
fccrdepend
ade
result
variat
structur
protein
epitop
amino
acid
level
investig
marburg
viru
marv
envelop
gp
two
strain
viru
angola
musok
reveal
angola
gp
antisera
notabl
enhanc
angola
pseudoviru
infect
wherea
musok
gp
antisera
significantli
enhanc
infect
angola
musok
pseudoviru
put
differ
pathogen
marv
strain
might
therefor
partli
explain
abil
induc
antibodi
enhanc
infect
function
analysi
angola
musok
gp
use
chimer
virus
identifi
epitop
mucinlik
region
glycin
amino
acid
posit
angola
gp
requir
maxim
ade
curious
alter
ade
significantli
mutat
gp
amino
acid
result
signific
chang
reactiv
angola
musok
gp
antisera
therefor
possibl
amino
acid
play
downstream
role
viru
entri
mediat
ade
pathway
yet
elucid
although
thought
signific
overlap
viral
epitop
respons
neutral
enhanc
infect
quantit
relationship
antibodymedi
neutral
ade
less
clear
recent
work
pierson
et
al
use
mab
rais
wnv
denv
shed
light
stoichiometri
process
agreement
previou
observ
ade
occur
presenc
subneutr
quantiti
antibodi
analys
neutral
fccrdepend
ade
suggest
two
phenomena
relat
differ
number
antibodi
bound
singl
virion
use
mab
bind
epitop
e
protein
upper
lower
threshold
number
mab
shown
dictat
stoichiometri
ade
neutral
threshold
govern
upper
limit
minimum
number
antibodi
requir
ade
found
approxim
half
number
requir
neutral
function
activ
mab
determin
locat
epitop
antibodi
affin
epitop
access
exampl
antibodi
recogn
poorli
access
epitop
often
incap
neutral
heterogen
virion
even
satur
condit
antibodi
highresolut
structur
studi
emphas
import
epitop
avail
ade
examin
greater
detail
conform
interact
viral
protein
play
key
role
bind
antibodi
also
cell
receptor
potenti
drug
studi
offer
comprehens
structur
data
analyz
antibodi
neutral
enhanc
infect
molecular
level
cryoelectron
microscopi
matur
form
denv
reveal
mark
differ
surfac
charg
distribut
number
contact
envelop
protein
serotyp
crystal
structur
antibodyenvelop
protein
interact
also
highlight
molecular
determin
infect
neutral
versu
enhanc
dynam
natur
certain
epitop
may
influenc
ade
mab
vari
degre
neutral
abil
denv
serotyp
strain
found
bind
highli
conserv
ab
loop
diii
e
protein
three
denv
serotyp
interestingli
epitop
poorli
access
matur
virion
suggest
signific
conform
chang
viru
take
place
antibodi
bind
therefor
reason
suppos
enhanc
antibodi
also
capabl
recogn
conceal
epitop
upon
conform
chang
virion
expos
allow
antibodi
bind
subsequ
ade
futur
studi
understand
structur
basi
ade
help
character
infectionenhanc
epitop
aid
ration
vaccin
drug
design
inde
highresolut
structur
use
silico
model
whole
viru
epitop
interact
antibodi
molecul
interest
pregnanc
mother
previous
concurr
infect
denv
transmit
denv
antibodi
develop
fetu
via
placenta
birth
via
breast
milk
protect
infant
homolog
infect
howev
level
protect
antibodi
drop
month
birth
disappear
month
period
either
subneutr
level
matern
antibodi
bind
virion
stoichiometri
vivo
neutral
threshold
nonneutr
matern
antibodi
may
enhanc
infect
increas
diseas
sever
may
explain
serolog
confirm
denvinfect
infant
south
vietnam
studi
develop
dhfdss
hand
prospect
nest
casecontrol
studi
filipino
infant
infect
show
correl
ade
activ
denv
diseas
sever
although
support
initi
vivo
protect
role
high
level
matern
deriv
antibodi
birth
show
decay
protect
antibodi
infant
ade
activ
determin
plaqu
reduct
neutral
titrat
cell
studi
attempt
correl
sever
diseas
determin
cytokin
level
howev
studi
sequenc
infect
time
particular
denv
strain
appear
modul
diseas
sever
ade
measur
human
thu
interpret
bear
mind
vitro
ade
activ
may
vari
depend
viru
strain
methodolog
mous
model
infect
serotyp
crossreact
antibodyopson
denv
mice
lack
type
ii
interferon
ifn
receptor
also
display
significantli
higher
mortal
albeit
lower
peak
serum
viremia
direct
viru
inocul
inde
viremia
human
necessarili
associ
denv
diseas
sever
evid
matern
deriv
antibodi
worsen
diseas
vivo
also
shown
mice
mice
born
immun
mother
infect
postnat
exhibit
higher
level
viremia
well
higher
level
tnf
correl
vascular
leakag
compar
control
mice
born
naiv
mother
correl
high
system
level
tnf
sever
diseas
also
found
vivo
experiment
ade
model
agreement
vitro
studi
either
fcrbear
cell
human
primari
myeloid
cell
show
higher
level
tnf
taken
togeth
may
also
reflect
involv
proinflammatori
cytokin
mechan
intrins
ade
nevertheless
fccriia
appear
permiss
fccr
denv
ade
human
question
whether
mous
model
without
equival
fccriia
reliabl
use
infer
ade
mechan
human
remain
unclear
although
transgen
murin
model
murin
fccr
replac
uniqu
human
fccr
may
enabl
insight
similarli
use
mice
pivot
receptor
innat
cellular
defens
adapt
type
respons
abrog
model
enhanc
viru
infect
vivo
remain
difficult
evalu
recent
studi
molecular
signal
event
involv
induct
ade
begun
shed
light
mechan
may
underli
phenomenon
ade
extrins
ade
facilit
viru
bind
entri
result
signific
increas
number
infect
cell
intrins
ade
subvert
antivir
state
within
individu
infect
cell
lead
infecti
virion
produc
releas
infect
cell
high
viral
load
due
increas
infect
cell
mass
ongo
condit
permiss
viru
replic
thought
presag
sever
diseas
develop
three
human
fccr
class
compris
fccri
fccrii
fccriii
fccri
highaffin
receptor
bind
monomer
igg
molecul
fccr
lowaffin
receptor
therefor
requir
multipl
interact
produc
suffici
highavid
bind
igg
immun
complex
transduc
relev
signal
fccriia
fccriic
activ
receptor
mostli
signal
via
immunoreceptor
tyrosinebas
activ
motif
itam
fccriib
known
inhibitori
fccr
contain
immunoreceptor
tyrosinebas
inhibitori
motif
itim
among
myeloid
cell
monocyt
express
fccri
fccriia
high
level
wherea
fccriib
express
intermedi
level
fccriia
fccriib
express
dc
fccriib
decreas
matur
ligat
viral
immun
complex
fccr
may
govern
ade
intern
pathway
outcom
ultim
balanc
activ
versu
inhibitori
fccr
pathogen
opson
result
format
igg
complex
activ
lowaffin
receptor
lead
viru
neutral
andor
phagocytosisintern
investig
denv
patient
healthi
individu
show
correl
serum
fccri
sever
diseas
denv
patient
despit
increas
level
patient
without
vascular
leakag
compar
healthi
subject
moreov
vitro
studi
use
fccriib
knockin
fccriib
knockdown
cell
show
fccriib
ligat
immunocomplex
inhibit
fccrmediat
phagocytosi
subsequ
reduc
denv
ade
interest
note
model
system
engag
immunocomplex
fccriib
dissoci
separ
direct
recycl
pathway
wherea
fccriia
ligand
undergo
degrad
process
via
lysosom
compart
cytoplasm
howev
pathway
may
still
oper
viral
infect
confirm
impli
suscept
denv
ade
appear
depend
ratio
activ
fccriia
inhibitori
fccriib
studi
human
primari
myeloid
cell
matur
immatur
dc
support
ade
fccriia
express
similar
level
matur
dc
immatur
dc
howev
matur
dc
lower
level
fccriib
immatur
dc
interestingli
immatur
dc
permiss
denv
infect
due
express
dcsign
denv
viral
receptor
found
lower
level
matur
dc
fccriibdefici
dc
also
exhibit
improv
capac
antigen
present
cell
compar
wildtyp
dc
indic
effect
antigen
uptak
fccriialig
immunocomplex
ratio
activ
fccriia
inhibitori
fccrii
favor
one
may
explain
differ
ade
profil
matur
immatur
dc
may
ultim
reflect
capac
enabl
ade
andor
probabl
occurr
although
ligat
occur
extracellular
compon
fccr
key
element
determin
behavior
fccr
isoform
locat
cytoplasm
domain
crucial
role
fccr
cytoplasm
tail
elegantli
demonstr
genet
exchang
itam
itim
activatinginhibitori
motif
notwithstand
function
intact
extracellular
compon
fccriiaitim
significantli
inhibit
ade
fccriibitam
restor
ade
wildtyp
level
consist
itam
mutat
remov
sequenc
two
tyrosin
itam
motif
elimin
abil
fccriia
mediat
ade
cell
mention
hallmark
ade
especi
vitro
increas
infect
viral
load
normal
condit
sever
intracellular
rna
sensor
includ
endosom
tolllik
receptor
tlr
recogn
doublestrand
rna
dsrna
singlestrand
rna
respect
fig
viral
rna
escap
endosom
like
recogn
tlrindepend
pathway
compon
retino
acidinduc
gene
melanoma
differentiationassoci
gene
recognit
dsrna
cell
typedepend
thu
rna
viru
infect
convent
dc
macrophag
isol
mice
fail
induc
ifn
wherea
ifn
product
still
observ
plasmacytoid
dc
upregul
rna
sensor
report
follow
denv
infect
monocyt
human
hepatomaderiv
cell
line
primari
dc
fig
tlr
activ
nuclear
transloc
transcript
factor
nfjb
via
pathway
produc
proinflammatori
cytokin
act
independ
via
trif
activ
induc
ifnb
although
rigi
recogn
differ
ligand
share
common
signal
featur
tlrdepend
pathway
recognit
dsrna
result
recruit
adapt
protein
interferonb
promot
stimul
mitochondri
outer
membran
consequ
activ
sever
transcript
factor
includ
nfjb
via
traf
famili
memberassoci
nfjb
activ
tank
bind
kinas
lead
express
type
ifn
variou
cytokin
newli
synthes
ifn
turn
via
jakstat
pathway
strongli
induc
antivir
nitric
oxid
upregul
express
howev
downstream
signal
inhibit
denv
cleav
sting
stimul
ifn
gene
human
disrupt
ifn
product
fig
moreov
also
produc
cleavag
activ
inflammasom
respect
upon
engag
virion
ctype
lectin
famili
member
surfac
molecul
macrophag
recent
produc
monocyt
vitro
shown
regul
antivir
respons
primari
cd
cell
denv
infect
cocultur
monocyt
cd
cell
addit
cd
cell
cultur
increas
ifnc
product
lysi
autolog
denvinfect
dc
surprisingli
although
cytokin
contribut
immun
cell
recruit
site
infect
promot
antivir
respons
blockad
interact
vivo
improv
surviv
rate
lethal
challeng
mice
howev
improv
surviv
may
attribut
defici
ifnc
signal
pathway
also
shown
ifncrdefici
mice
togeth
tlrdepend
tlrindepend
pathway
induc
variou
proinflammatori
cytokin
includ
ifnab
tailor
innat
antivir
respons
activ
defens
variou
cell
denv
infect
regul
also
intim
link
activ
fccr
ligat
immunocomplex
fccriia
intern
fccriiaimmunocomplex
enter
endosom
compart
low
affin
fccriia
facilit
releas
immunocomplex
unknown
pathway
ligat
dissoci
fccriiaimmunocomplex
alter
innat
respons
antivir
immunesuppress
induc
tnf
suppress
express
type
ifn
sever
possibl
may
explain
intrins
ade
firstli
ade
may
sabotag
tlrindepend
antivir
pathway
downregul
rigi
express
promot
dihydroxyaceton
kinas
dak
autophagyrel
protein
product
fig
invers
relationship
dak
observ
monocytederivedmacrophag
secondli
ligat
fccrimmunocomplex
modul
cytokin
product
upregul
tnf
report
sever
human
investig
denv
infect
intriguingli
recent
consid
reliabl
biomark
predict
clinic
sever
although
data
fccrmediat
cytokin
respons
context
denv
ade
variabl
increas
tnf
product
consist
shown
monocyt
macrophag
dc
upon
exposur
immunocomplex
differ
studi
may
attribut
antibodi
differ
certainli
virusspecif
memori
b
cellderiv
mab
isol
use
recombin
antigen
may
exclud
potenti
neutral
antibodi
bind
conform
epitop
vitro
hand
neutral
antibodi
subneutr
concentr
might
also
induc
ade
fcrbear
cell
fccrmediat
cytokin
product
determin
ratio
activ
inhibitori
fccr
thu
simultan
stimul
activ
inhibitori
fccr
may
induc
signific
cytokin
product
without
synerg
contribut
addit
signal
eg
tlr
inde
cytokin
product
like
due
crosstalk
fccriia
report
ligat
iggopson
bacteria
studi
use
denv
ade
cell
show
invers
relationship
express
express
sterilealpha
armadillo
motifcontain
protein
sarm
tank
upregul
sarm
tank
led
downregul
tlr
signal
molecul
significantli
use
nfjb
signal
fig
although
tank
implic
posit
regul
well
nfjb
recent
shown
neg
regul
activ
tlr
signal
directli
bind
inhibit
ubiquityl
lead
inhibit
nfjb
activ
inhibit
nfjb
result
reduct
ifnab
well
express
undermin
product
induc
via
jakstat
pathway
contrast
tnf
higher
ade
denv
product
cell
significantli
reduc
lower
serum
level
also
observ
dhf
patient
higher
level
acut
febril
phase
compar
patient
mild
dengu
fever
suggest
denv
suppress
howev
data
denv
infect
conflict
nitric
oxid
synthas
express
substanti
induc
activ
monocyt
signific
number
dengu
patient
monocyt
high
express
associ
reduc
denv
antigen
express
vitro
anim
model
mice
inocul
intraperiton
mouseadapt
show
mortal
compar
wildtyp
control
suggest
presenc
may
help
control
denv
may
also
involv
immunopathogenesi
exampl
larginineno
pathway
platelet
activ
dhf
patient
argu
contribut
bleed
diathesi
seen
patient
line
studi
prospect
longitudin
adult
studi
patient
dhf
nondhf
febril
ill
show
level
correl
develop
dhf
notion
support
anoth
studi
intracrani
mous
model
mice
show
surviv
compar
mortal
seen
wildtyp
mice
thu
evid
play
role
viru
control
may
also
respons
lethal
reach
neurotox
level
brain
discrep
two
studi
mice
like
explain
differ
viru
strain
use
mouseadapt
model
viru
replic
effect
brain
caus
death
infect
cell
may
reduc
neurovirul
help
control
viru
spread
elev
antivir
role
murin
model
neurotrop
flavivirus
also
demonstr
immunopatholog
role
ade
condit
suppressor
cytokin
signal
upregul
appear
respons
inhibit
jakstat
pathway
monocytederiv
macrophag
increas
express
cell
high
level
fig
denv
adeinduc
product
shown
control
fccr
synerg
tlr
orchestr
induct
cytokin
promot
dak
dihydroxi
aceton
kinas
autophagyrel
protein
sarm
sterilealpha
armadillo
motifcontain
protein
tank
traf
famili
memberassoci
nuclear
factor
kappab
activ
downregul
rigi
express
sabotag
tlrindepend
antivir
pathway
subsequ
suppress
product
type
ifn
b
colig
fccr
leukocyt
immunoglobulinlik
denvimmun
complex
denv
virion
respect
inhibit
activ
syk
abrog
express
isg
c
ligat
fccr
immun
complex
also
induc
upregul
via
syk
spleen
tyrosin
kinasemedi
phosphoinositid
kinas
activ
activ
well
trigger
soc
suppressor
cytokin
signal
pathway
inhibit
jakstat
signal
pathway
decreas
proinflammatori
cytokin
product
itim
immunoreceptor
tyrosinebas
inhibitori
motif
itam
immunoreceptor
tyrosinebas
activ
motif
src
homolog
protein
tyrosin
pkb
protein
kinas
b
glycogen
synthas
kinas
creb
cyclic
adenosin
monophosph
respons
elementbind
tyk
tyrosin
kinas
activ
cyclic
adenosin
monophosph
respons
element
bind
creb
achiev
mainli
phosphoinositid
pkb
pathway
protein
kinas
activ
fig
upstream
signal
event
ligat
fccriiaimmunocomplex
engag
virion
partli
induc
spleen
tyrosin
kinas
syk
mediat
activ
activ
phosphoryl
inactiv
glycogen
synthas
kinas
gsk
fig
import
regul
product
follow
tlr
signal
inactiv
downregul
creb
stabil
activ
result
observ
high
level
howev
activ
syk
via
itam
intracellular
domain
fccriia
also
induc
express
type
ifnstimul
gene
isg
ifnindepend
manner
thu
clear
denvimmunocomplex
facilit
ade
ligat
fccr
immunocomplex
enhanc
product
isg
mani
identifi
effici
antivir
factor
denv
well
wnv
note
syk
activ
fccriia
signal
cascad
appear
tightli
regul
prevent
exagger
inflammatori
respons
immun
complex
contain
harmless
antigen
may
present
circul
time
regul
accomplish
balanc
activ
itam
inhibitori
itim
signal
inde
absenc
inhibitori
itim
signal
associ
autoimmun
diseas
inhibitori
activ
signal
via
immunoreceptor
pathway
involv
activ
src
famili
kinas
follow
engag
fccr
immunocomplex
howev
activ
signal
util
activ
src
activ
syk
activ
src
inhibitori
signal
pathway
lead
recruit
either
inositol
phosphatas
ship
src
homolog
inositol
polyphosph
tyrosin
phosphatas
src
homolog
protein
tyrosin
subsequ
dampen
downstream
signal
respons
dephosphoryl
syk
context
denvimmunocomplex
may
exploit
inhibitori
itim
signal
subvert
express
isg
mention
previous
fccriib
one
common
itimcontain
transmembran
protein
myeloid
cell
howev
denvimmunocomplex
fail
bind
fccriib
subneutr
level
antibodi
establish
ade
addit
ligat
denvimmunocomplex
fccriib
achiev
high
concentr
antibodi
induc
ade
recent
studi
exploit
differ
induc
ade
subclon
cell
found
bind
leukocyt
immunoglobulinlik
denv
virion
may
inhibit
activ
syk
abrog
express
isg
fig
itimcontain
transmembran
protein
express
cell
nk
cell
b
cell
primarili
myeloid
cell
inhibitori
effect
also
shown
monocyt
lineag
variou
diseas
follow
receptor
engag
src
famili
protein
tyrosin
kinas
phosphoryl
tyrosin
residu
itim
recruit
either
inositol
phosphatas
ship
stage
activ
phosphoryl
dephosphoryl
inactiv
syk
thu
ligat
denvimmunocomplex
fccriia
bind
denv
virion
synergist
induc
intrins
ade
cell
surfac
pathway
control
syk
appear
conflict
thu
clear
whether
inhibit
syk
may
lead
reduct
product
ade
condit
may
involv
tempor
balanc
inhibit
activ
syk
yet
elucid
base
data
patient
sever
denv
infect
balanc
presum
tune
favor
excess
product
target
fc
receptor
intraven
immunoglobulin
infus
possibl
therapeut
avenu
treatment
viral
diseas
intraven
immunoglobulin
ivig
blood
product
consist
pool
igg
fraction
obtain
approxim
plasma
specimen
blood
donor
sinc
discoveri
year
ago
ivig
convent
use
therapeut
treatment
immunocompromis
individu
suffer
immun
defici
diseas
hypogammaglobulinemia
immunocompromis
individu
highli
suscept
pathogen
infect
henc
infus
wellprocess
ivig
prepar
undergon
viru
inactiv
deplet
blood
coagul
factor
igg
aggreg
crucial
enabl
protect
pathogen
avoid
deleteri
effect
could
elicit
infus
date
despit
efficaci
ivig
treatment
sever
autoimmun
inflammatori
diseas
mechan
ivig
remain
illdefin
current
possibl
mechan
underli
ivig
efficaci
mainli
revolv
around
abil
shape
immun
respons
one
possibl
mechan
infus
highdos
ivig
prevent
fccr
activ
satur
bind
receptor
infus
igg
well
increas
express
inhibitori
fccriib
immunomodul
infus
igg
stem
interact
fc
variabl
domain
igg
fccr
earlier
section
review
discuss
pathogen
impact
subneutr
antibodi
interact
fc
receptor
viral
invas
caus
ade
assess
possibl
therapeut
role
ivig
infus
world
preval
arthropodtransmit
viru
infect
possibl
complic
may
aris
treatment
presenc
ade
infect
highdos
ivig
commonli
use
treatment
wnv
enceph
among
arthropodborn
diseas
potenti
ivig
infus
amelior
wnv
enceph
report
experiment
clinic
earliest
studi
conduct
engl
diamond
passiv
transfer
serum
mice
surviv
primari
wnv
infect
wt
mice
prevent
morbid
mortal
subsequ
wnv
infect
although
passiv
transfer
immun
sera
fail
prevent
mortal
immunecompromis
b
celldefici
lmt
mice
mice
surviv
longer
period
time
rang
day
post
infect
compar
typic
surviv
control
mice
subsequ
work
murin
model
lethal
wnv
enceph
demonstr
increas
surviv
rate
follow
ivig
administr
particularli
ivig
deriv
donor
wnv
endem
region
israelwhich
like
contain
antiwnv
antibodi
inde
presenc
antiwnv
antibodi
ivig
prepar
collect
us
donor
protect
mice
lethal
dose
wnv
recent
srivastava
et
al
shed
insight
mechan
underli
ivig
efficaci
anim
model
identifi
ivig
prepar
contain
antibodi
wnv
capabl
dampen
inflammatori
monocyt
high
infiltr
central
nervou
system
henc
limit
extent
inflamm
prolong
surviv
wnv
mous
model
consist
recent
studi
gett
et
al
demonstr
therapeut
modul
inflammatori
monocyt
immigr
cn
use
immunemodifi
microparticl
significantli
increas
surviv
wnv
mous
model
addit
success
ivig
treatment
observ
anim
studi
grow
evid
pinpoint
therapeut
potenti
ivig
report
clinic
context
infus
ivig
prepar
contain
high
titer
antiwnv
antibodi
prevent
develop
neuroinvas
wnv
diseas
patient
contract
wnv
infect
liver
transplant
obtain
infect
individu
rapid
efficaci
passiv
immunoprophylaxi
ivig
evidenc
clinic
studi
perform
shimoni
et
al
wnv
patient
exhibit
neuroinvas
sign
given
ivig
administr
although
cohort
die
neurolog
complic
either
partial
complet
recov
patient
experienc
rapid
improv
clinic
condit
earli
h
post
ivig
treatment
suggest
potenti
ivig
infus
treat
lethal
case
wnv
neuroinvas
diseas
despit
efficaci
ivig
treat
wnv
infect
effect
ivig
treatment
denv
infect
controversi
sever
form
denv
infect
give
rise
potenti
lethal
sever
thrombocytopenia
shock
syndrom
ivig
wide
use
treatment
immunothrombocytopenia
give
posit
medic
outcom
dhf
outbreak
brazil
five
clinic
diagnos
dhf
patient
given
high
dose
ivig
rapid
reduct
bleed
diathesi
immedi
recoveri
platelet
count
patient
suggest
ivig
potenti
treat
dhf
furthermor
clinic
studi
intraven
antid
igg
immun
globulin
administ
children
adult
patient
cohort
secondari
denv
infect
result
increas
platelet
count
children
exhibit
sever
thrombocytopen
purpura
howev
random
control
clinic
studi
report
opposit
result
patient
acut
secondari
denv
infect
random
highdos
ivigtr
untreat
group
despit
earli
administr
ivig
neither
improv
thrombocytopenia
advers
side
effect
observ
moreov
recent
anim
studi
immunocompet
mous
model
secondari
denv
infect
demonstr
increas
mortal
exacerb
diseas
sever
elev
viru
replic
observ
ivigtr
mice
dosedepend
manner
examin
reveal
subneutr
titer
antidenv
antibodi
recov
serum
ivigtr
mice
contribut
factor
deleteri
outcom
experiment
clinic
studi
warrant
examin
exact
effect
ivig
denv
infect
possibl
advers
effect
ivig
denv
ade
infect
therapeut
potenti
ivig
treatment
inflammatori
arthrit
diseas
rheumatoid
arthriti
ra
well
establish
recent
studi
campbel
et
al
demonstr
import
igg
fc
portion
contribut
efficaci
ivig
antiinflammatori
effect
ra
mous
model
addit
report
use
chikv
rrv
murin
diseas
model
identifi
bone
patholog
resembl
ra
relev
anim
studi
support
emerg
clinic
evid
chikv
patient
develop
persist
symmetr
polyarthr
mimic
seroneg
ra
efficaci
ivig
treatment
ra
suggest
may
possibl
therapeut
candid
treatment
alphavirusinduc
persist
arthriti
clinic
manifest
chikv
infect
typic
selflimit
howev
medic
complic
aris
infect
associ
occasion
mortal
recent
chikv
outbreak
america
juli
led
suspect
confirm
autochthon
transmiss
case
infect
death
report
mainli
latin
america
caribbean
region
despit
typic
low
fatal
ratio
associ
chikv
infect
substanti
increas
mortal
report
indian
ocean
chikv
outbreak
date
exact
caus
underli
increas
mortal
unclear
howev
medic
complic
fulmin
hepat
neurolog
cardiolog
manifest
associ
chikvinduc
fatal
previous
clinic
case
studi
report
outcom
chikv
patient
given
highdos
ivig
treatment
diagnos
neurolog
complic
patient
exhibit
febril
ill
polyarthralgia
acut
phase
infect
rapidli
subsid
within
week
post
diseas
onset
howev
convalesc
phase
infect
neurolog
complic
led
quadriparesi
myeloneuropathi
observ
subsequ
infus
highdos
ivig
rapidli
amelior
complic
led
complet
recoveri
followup
month
clinic
case
studi
consist
earlier
studi
lebrun
et
al
report
rapid
recoveri
ivig
treatment
two
chikv
patient
lateonset
neuropathi
guillainbarr
e
syndrom
surprisingli
ivig
treatment
chikv
patient
earli
onset
neurolog
manifest
led
exacerb
diseas
suggest
stage
infect
clinic
manifest
exhibit
care
assess
prior
ivig
infus
avoid
harm
side
effect
treatment
precautionari
measur
determin
level
acut
phase
innat
immun
protein
pentraxin
ivig
plasma
prepar
well
patient
blood
specimen
also
taken
consider
highli
express
panel
inflammatori
diseas
disord
recent
elev
express
report
acut
rrv
chikv
patient
subsequ
experiment
studi
character
pathogen
consequ
overt
express
enhanc
alphaviru
replic
caus
earli
diseas
onset
prolong
diseas
manifest
therefor
prevent
measur
exacerb
diseas
ivig
prepar
high
level
protein
given
chikvrrv
patient
addit
high
level
express
patient
kawasaki
diseas
associ
unrespons
ivig
treatment
henc
ivig
treatment
acut
rrvchikv
patient
also
avoid
due
high
level
alphavirusinduc
express
earli
phase
infect
precautionari
measur
mind
studi
look
effect
administ
ivig
contain
low
level
convalesc
phase
infect
might
provid
new
insight
efficaci
ivig
treatment
alphaviru
diseas
manifest
numer
host
virusspecif
stimuli
affect
cours
viru
infect
diseas
pathogenesi
host
ade
viral
infect
occur
preexist
virusspecif
antibodi
aid
uptak
viru
cell
bear
fc
receptor
drive
complementdepend
infect
enhanc
promot
viru
particl
product
earli
infect
whether
fcrdepend
ade
infect
play
role
viral
infect
depend
number
factor
includ
infect
viru
strain
antibodi
concentr
epitop
avail
find
date
partli
explain
interact
intracellular
antivir
suppress
extrins
role
enhanc
antibodi
viral
uptak
produc
ade
phenomenon
observ
sever
virus
particular
dhfdss
patient
although
much
understand
base
denv
studi
evid
ade
virus
suggest
phenomenon
wide
generaliz
take
dengu
fever
work
model
assum
ade
viru
strainindepend
infer
antibodi
opson
virion
determin
function
profil
antibodi
neutralizingcrossreactivenonneutr
rel
affin
thereof
access
relev
viral
epitop
immun
complex
ligat
activ
inhibitori
fccr
bind
occur
cytoplasm
itam
itim
domain
deliv
immunocomplex
via
phagocyt
recycl
pathway
respect
cell
immunocomplex
intern
via
phagocyt
fccriia
pathway
uncoat
within
endosom
viral
rna
recogn
tlr
fccr
synerg
tlr
orchestr
induct
cytokin
howev
paradox
denv
seem
also
exploit
inhibitori
itim
signal
pathway
via
inhibit
syk
thu
express
isg
otherwis
promot
syk
activ
follow
ligat
fccriia
denvimmunocomplex
thu
interact
fccriia
denvimmunocomplex
denv
virion
respect
synergist
shift
immun
system
antivir
immunosuppress
state
thu
although
still
poorli
defin
outcom
ade
evid
balanc
activ
inhibitori
element
pathway
although
understand
viru
ade
increas
substanti
last
decad
import
question
remain
dispar
studi
highlight
difficulti
interpret
respons
differ
cell
type
infect
differ
denv
strain
like
appli
virus
also
signific
interest
identifi
factor
contribut
balanc
activ
inhibit
syk
regul
antivir
isg
versu
antiinflammatori
potenti
immunosuppress
whether
adeassoci
product
also
control
syk
activ
extent
induct
pathway
common
separ
interest
undoubtedli
need
find
accept
vivo
model
confirm
find
much
elucid
ade
mechan
come
vitro
studi
use
monocyt
line
primari
human
myeloid
cell
lack
analog
murin
equival
fccriia
make
investig
difficult
